Literature DB >> 9658399

Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

J M Kokontis1, N Hay, S Liao.   

Abstract

The molecular mechanism of androgen-independent growth of prostate cancer after androgen ablation was explored in LNCaP cells. An androgen-dependent clonal subline of the LNCaP human prostate carcinoma cell line, LNCaP 104-S, progressed to a slow growing stage (104-R1) and then to a faster growing stage (104-R2) during more than 2 yr of continuous culture in the absence of androgen. Androgen-induced proliferation of 104-S cells is inhibited by the antiandrogen Casodex, while proliferation of 104-R1 and 104-R2 cells is unaffected by Casodex. This indicates that proliferation of 104-R1 and 104-R2 cells is not supported by low levels of androgen in the culture medium. Compared with LNCaP 104-S cells, both 104-R1 and 104-R2 cells express higher basal levels of androgen receptor (AR), and proliferation of these two cell lines is paradoxically repressed by androgen. After continuous passage in androgen-containing medium, 104-R1 cells reverted back to an androgen-dependent phenotype. The mechanism of androgenic repression of 104-R1 and 104-R2 sublines was further evaluated by examining the role of critical regulatory factors involved in the control of cell cycle progression. At concentrations that repressed growth, androgen transiently induced the expression of the cyclin-dependent kinase (cdk) inhibitor p21waf1/cip1 in 104-R1 cells, while expression of the cdk inhibitor p27Kip1 was persistently induced by androgen in both 104-R1 and 104-R2 cells. Induced expression of murine p27Kip1 in 104-R2 cells resulted in G1 arrest. Specific immunoprecipitates of Cdk2 but not Cdk4 from androgen-treated 104-R1 cells contained both p21waf1/cip1 and p27Kip1. This observation was confirmed by in vitro assay of histone H1 and Rb (retinoblastoma protein) phosphorylation by the proteins associated with the immune complex. Furthermore, inhibition of Cdk2 activity correlated with the accumulation of p27Kip1 and not p21waf1/cip1. From these results we conclude that androgenic repression of LNCaP 104-R1 and 104-R2 cell proliferation is due to the induction of p27Kip1, which in turn inhibits Cdk2, a factor critical for cell cycle progression and proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658399     DOI: 10.1210/mend.12.7.0136

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  80 in total

1.  Chinese red yeast rice inhibition of prostate tumor growth in SCID mice.

Authors:  Mee Young Hong; Susanne Henning; Aune Moro; Navindra P Seeram; Yanjun Zhang; David Heber
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

Review 2.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 3.  Regulation of mitochondrial DNA content and cancer.

Authors:  Masahiro Higuchi
Journal:  Mitochondrion       Date:  2006-12-05       Impact factor: 4.160

4.  SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells.

Authors:  Jung Hwa Kim; Ji Min Lee; Hye Jin Nam; Hee June Choi; Jung Woo Yang; Jason S Lee; Mi Hyang Kim; Su-Il Kim; Chin Ha Chung; Keun Il Kim; Sung Hee Baek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

5.  Androgen and its receptor promote Bax-mediated apoptosis.

Authors:  Yuting Lin; John Kokontis; Fangming Tang; Bradley Godfrey; Shutsung Liao; Anning Lin; Youting Chen; Jialing Xiang
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

6.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Authors:  Michael J Morris; Daisy Huang; William K Kelly; Susan F Slovin; Ryan D Stephenson; Caitlin Eicher; Anthony Delacruz; Tracy Curley; Lawrence H Schwartz; Howard I Scher
Journal:  Eur Urol       Date:  2009-04-03       Impact factor: 20.096

7.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

8.  Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Authors:  Joanna Nightingale; Khurram S Chaudhary; Paul D Abel; Andrew P Stubbs; Hanna M Romanska; Stephen E Mitchell; Gordon W H Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

9.  Androgens transduce the G alphas-mediated activation of protein kinase A in prostate cells.

Authors:  Gargi Bagchi; Juanjuan Wu; John French; Jae Kim; Nader H Moniri; Yehia Daaka
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

10.  Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Authors:  Mark A Castanares; Ben T Copeland; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Martin G Pomper; Shawn E Lupold; Catherine A Foss
Journal:  Prostate       Date:  2015-10-26       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.